| 1 | The interaction of β-arrestin1 with talin1 driven by endothelin A receptor as a feature of α5β1 integrin activation in high-grade serous ovarian cancer | 8.5 | 8 | Citations (PDF) |
| 2 | Exploring the Control of PARP1 Levels in High-Grade Serous Ovarian Cancer | 4.0 | 0 | Citations (PDF) |
| 3 | Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients | 11.5 | 17 | Citations (PDF) |
| 4 | Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application | 5.6 | 24 | Citations (PDF) |
| 5 | What’s beyond BRCA Mutational Status in High Grade Serous Ovarian Cancer? The Impact of Hormone Receptor Expression in a Large BRCA-Profiled Ovarian Cancer Patient Series: A Retrospective Cohort Study | 4.0 | 1 | Citations (PDF) |
| 6 | Translational Research in the Era of Precision Medicine: Where We Are and Where We Will Go | 2.7 | 71 | Citations (PDF) |
| 7 | In search for biomarkers and potential drug targets for uterine serous endometrial cancer | 2.4 | 8 | Citations (PDF) |
| 8 | Stat1 confers sensitivity to radiation in cervical cancer cells by controlling Parp1 levels: a new perspective for Parp1 inhibition | 8.5 | 15 | Citations (PDF) |
| 9 | Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational Study | 4.0 | 10 | Citations (PDF) |
| 10 | KLF7: a new candidate biomarker and therapeutic target for high-grade serous ovarian cancer | 11.5 | 24 | Citations (PDF) |
| 11 | Clinical Value of lncRNA MEG3 in High-Grade Serous Ovarian Cancer | 4.0 | 25 | Citations (PDF) |
| 12 | Estrogens Counteract Platinum-Chemosensitivity by Modifying the Subcellular Localization of MDM4 | 4.0 | 5 | Citations (PDF) |
| 13 | A combined ANXA2-NDRG1-STAT1 gene signature predicts response to chemoradiotherapy in cervical cancer | 11.5 | 19 | Citations (PDF) |
| 14 | Preoperative Anti-Class III β-Tubulin Antibodies As Relevant Clinical Biomarkers in Ovarian Cancer | 3.8 | 2 | Citations (PDF) |
| 15 | Identification and antitumor activity of a novel inhibitor of the NIMA-related kinase NEK6 | 3.7 | 28 | Citations (PDF) |
| 16 | Estrogen receptor β: Potential target for therapy in adult granulosa cell tumors? | 1.6 | 22 | Citations (PDF) |
| 17 | Hormone receptor expression profile of low-grade serous ovarian cancers | 1.6 | 31 | Citations (PDF) |
| 18 | Uncovering the role of nuclear Lysyl oxidase (LOX) in advanced high grade serous ovarian cancer | 1.6 | 27 | Citations (PDF) |
| 19 | Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts | 8.5 | 68 | Citations (PDF) |
| 20 | The relevance of prelamin A and RAD51 as molecular biomarkers in cervical cancer | 1.7 | 10 | Citations (PDF) |
| 21 | Targeting the hallmarks of ovarian cancer: The big picture | 1.6 | 29 | Citations (PDF) |
| 22 | Sexual dimorphism in medulloblastoma features | 3.9 | 12 | Citations (PDF) |
| 23 | Ovarian low and high grade serous carcinomas: hidden divergent features in the tumor microenvironment | 1.7 | 22 | Citations (PDF) |
| 24 | Multiple direct and indirect mechanisms drive estrogen-induced tumor growth in high grade serous ovarian cancers | 1.7 | 40 | Citations (PDF) |
| 25 | Mitochondrial estrogen receptor β2 drives antiapoptotic pathways in advanced serous ovarian cancer | 2.4 | 15 | Citations (PDF) |
| 26 | Letter to the Editor: Estrogen and Medulloblastoma | 2.7 | 1 | Citations (PDF) |
| 27 | Use of phytoestrogens in menopause | 2.8 | 0 | Citations (PDF) |
| 28 | Prognostic significance of the estrogen receptor beta (ERβ) isoforms ERβ1, ERβ2, and ERβ5 in advanced serous ovarian cancer | 1.6 | 51 | Citations (PDF) |
| 29 | Gender Effect in Experimental Models of Human Medulloblastoma: Does the Estrogen Receptor β Signaling Play a Role? | 2.5 | 16 | Citations (PDF) |
| 30 | The expression ratios of estrogen receptor α (ERα) to estrogen receptor β1 (ERβ1) and ERα to ERβ2 identify poor clinical outcome in endometrioid endometrial cancer | 2.4 | 41 | Citations (PDF) |
| 31 | Expression of the Glioma-Associated Oncogene Homolog 1 (Gli1) in Advanced Serous Ovarian Cancer Is Associated with Unfavorable Overall Survival | 2.5 | 43 | Citations (PDF) |
| 32 | Clinicopathologic and Immunohistochemical Features of Ovarian Clear Cell Carcinomas in Comparison With Type I and Type II Tumors | 1.6 | 23 | Citations (PDF) |
| 33 | Estrogen Receptor Beta in Cancer: an Attractive Target for Therapy | 2.3 | 50 | Citations (PDF) |
| 34 | The dualistic model of endometrial cancer: The challenge of classifying grade 3 endometrioid carcinoma | 1.6 | 11 | Citations (PDF) |
| 35 | Prognostic role of metastasis tumor antigen 1 in patients with ovarian cancer: a clinical study | 2.4 | 27 | Citations (PDF) |
| 36 | The estrogen receptor beta agonist diarylpropionitrile (DPN) inhibits medulloblastoma development via anti-proliferative and pro-apototic pathways | 8.5 | 22 | Citations (PDF) |
| 37 | Changes in the expression of oestrogen receptors and E‐cadherin as molecular markers of progression from normal epithelium to invasive cancer in elderly patients with vulvar squamous cell carcinoma | 3.9 | 29 | Citations (PDF) |
| 38 | Cytoplasmic expression of oestrogen receptor beta (ERβ) as a prognostic factor in vulvar squamous cell carcinoma in elderly women | 3.9 | 11 | Citations (PDF) |
| 39 | Cytoplasmic expression of estrogen receptor beta (ERβ) predicts poor clinical outcome in advanced serous ovarian cancer | 1.6 | 66 | Citations (PDF) |
| 40 | The Epithelial-Mesenchymal Transition and the Estrogen-Signaling in Ovarian Cancer | 2.0 | 30 | Citations (PDF) |
| 41 | Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical–pathological and immunohistochemical study | 2.7 | 48 | Citations (PDF) |
| 42 | Protective role of 17β‐estradiol on medulloblastoma development in <i>Patched1</i> heterozygous mice | 4.5 | 12 | Citations (PDF) |
| 43 | Hyaluronic acid–paclitaxel: effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts | 2.3 | 45 | Citations (PDF) |
| 44 | Paclitaxel Directly Binds to Bcl-2 and Functionally Mimics Activity of Nur77 | 0.6 | 136 | Citations (PDF) |
| 45 | Modulation of basal and squamous cell carcinoma by endogenous estrogen in mouse models of skin cancer | 2.9 | 59 | Citations (PDF) |
| 46 | Re: Modulation of basal and squamous cell carcinoma by endogenous estrogen in mouse models of skin cancer | 2.9 | 2 | Citations (PDF) |
| 47 | Cells with Characteristics of Cancer Stem/Progenitor Cells Express the CD133 Antigen in Human Endometrial Tumors | 6.4 | 140 | Citations (PDF) |
| 48 | Antiproliferative and antiangiogenic effects of the benzophenanthridine alkaloid sanguinarine in melanoma | 5.1 | 80 | Citations (PDF) |
| 49 | Molecular Mechanisms of Patupilone Resistance | 0.6 | 55 | Citations (PDF) |
| 50 | New taxanes in development | 4.1 | 31 | Citations (PDF) |
| 51 | 17β-Estradiol and soy phytochemicals selectively induce a type 2 polarization in mesenteric lymph nodes of ovariectomized rats | 1.9 | 8 | Citations (PDF) |
| 52 | Soy Phytochemicals Decrease Nonsmall Cell Lung Cancer Growth In Female Athymic Mice3 | 3.0 | 30 | Citations (PDF) |
| 53 | Estradiol and phytoestrogens differently influence the rodent postmenopausal mammary gland | 1.9 | 14 | Citations (PDF) |
| 54 | The role of phytochemicals in menopause | 1.9 | 0 | Citations (PDF) |
| 55 | Preclinical in vivo activity of a combination gemcitabine/liposomal doxorubicin against cisplatin-resistant human ovarian cancer (A2780/CDDP) | 2.3 | 12 | Citations (PDF) |
| 56 | Lack of stimulatory activity of a Phytoestrogen-containing soy extract on the growth of breast cancer tumors in mice | 2.9 | 26 | Citations (PDF) |
| 57 | Characterization of the pharmacologic profile of a standardized soy extract in the ovariectomized rat model of menopause: effects on bone, uterus, and lipid profile | 1.9 | 33 | Citations (PDF) |
| 58 | Thiocolchicine dimers: a novel class of topoisomerase-I inhibitors | 5.1 | 27 | Citations (PDF) |
| 59 | The Seco-Taxane IDN5390 Is Able to Target Class III β-Tubulin and to Overcome Paclitaxel Resistance | 0.6 | 99 | Citations (PDF) |
| 60 | Gemcitabine: current role and future options in the treatment of ovarian cancer | 5.3 | 22 | Citations (PDF) |
| 61 | Antitumour activity of the silybin-phosphatidylcholine complex, IdB 1016, against human ovarian cancer | 3.3 | 69 | Citations (PDF) |
| 62 | Bcl-2 Down-Regulation Is a Novel Mechanism of Paclitaxel Resistance | 2.8 | 122 | Citations (PDF) |
| 63 | Second Generation Taxanes: from the Natural Framework to the Challenge of Drug Resistance | 7.3 | 26 | Citations (PDF) |
| 64 | Silybin and its bioavailable phospholipid complex (IdB 1016) potentiate in vitro and in vivo the activity of cisplatin | 4.5 | 61 | Citations (PDF) |
| 65 | Dietary soy modulation of biochemical parameters in DMBA-induced mammary tumors | 8.5 | 11 | Citations (PDF) |
| 66 | Chemoprevention of DMBA-induced mammary cancer in rats by dietary soy | 2.5 | 48 | Citations (PDF) |
| 67 | Clinical Effects of a Standardized Soy Extract in Postmenopausal Women | 1.9 | 180 | Citations (PDF) |
| 68 | Anti-tumour activity of a panel of taxanes toward a cellular model of human cervical cancer | 2.3 | 5 | Citations (PDF) |
| 69 | Reproductive Effects of Dietary Soy in Female Wistar Rats | 3.6 | 39 | Citations (PDF) |
| 70 | Discovery of a Selective NEK6 Kinase Inhibitor by Virtual Screening | 0.0 | 0 | Citations (PDF) |
